Q-omics provides the consensus-scored MYOZ3 profile across patient tissues and cancer cell-line models. MYOZ3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYOZ3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MYOZ3 RNA expression shows 20,179 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KICH, and PDAC as cancer lineages where MYOZ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYOZ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYOZ3 survival associations across molecular data types. MYOZ3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYOZ3 RNA expression–survival associations across cancer types. High MYOZ3 expression shows unfavorable associations in ACC, KIRP, CESC and LGG, but favorable associations in BRCA and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYOZ3 RNA expression.
This table summarizes MYOZ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYOZ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYOZ3 shows lower tumor expression in KICH, LUSC, LUAD, THCA, HNSC and COAD. The KICH box plot shows higher MYOZ3 RNA expression in normal versus tumor tissue (log2 FC = −0.564, t-test p < 0.001).
This table shows molecular features associated with MYOZ3 in patient tissues and cancer cell lines. In patient samples, MYOZ3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYOZ3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BONE.
